整理 | GLP1减重宝典内容团队 2026 年，全球代谢疾病治疗赛道迎来关键转折点，礼来一口气推进三款重磅新药上市，覆盖口服、双靶点、三靶点三大技术路线，有望彻 底改写现有减重与降糖市场规则，为患者带来更高效、便捷的治疗新选择。 | Phase 3 Initiations | | Regulatory Submissions | | --- | --- | --- | | 2 Eloralintide for obesity or overweight | | Orforglipron for type 2 diabetes [US/ EU ©/J] | | ට | Eloralintide incretin add-on for obesity or overweight | Orforglipron for obstructive sleep apnea and obesity or overweight | | O Eloralintide for OA knee pain | | Retatrutide for overweight or obesity | | 2 Eloralintide for ...